JNJ Johnson & Johnson

$JNJ $MRNA $SLS MRNA Shorts have been squeezed from $25 to $243+ on there Phase 3 cancer vaccine success. $SLS will ascend in the same pattern in the coming hours and days ahead as we approach The next Chapter. ✌️🙏❤️‍🩹

$JNJ I would love to see the JnJ CEO give updates on acquisitions and talk about what they are doing to make sure they reach valuable assets before competitors do! $SLS

With $JNJ being mentioned again in discussions around a potential $SLS acquisition, it’s worth revisiting some interesting connections. • JNJ has a major hematology/oncology franchise and the global infrastructure to commercialize GPS. • REGAL Phase 3 is approaching its final OS readout. Strong results could significantly increase GPS’s strategic value. • SLS009 represents a second oncology asset with potential applications beyond AML. • SLS director Katherine Bach Kalin previously held senior positions at both JNJ and Celgene. • JNJ Innovative Medicine chairman Tom Cavanaugh also has a significant Celgene background. • SLS director Robert Van Nostrand was associated with Intra-Cellular Therapies, acquired by JNJ for approximately $14.6B. • A JNJ employee has also publicly expressed interest in GPS on LinkedIn. Coincidence? Maybe, maybe not...

$JNJ $SLS $MRK This is Merck's war to lose, and J&J is the wolf at the door. If Johnson & Johnson captures the $SLS platform, Merck ($MRK) faces absolute oncological extinction.

$JNJ $SLS Part 3. Johnson & Johnson (JNJ) has an estimated near-term “firepower" or buyout capacity of $30 billion to $40 billion without risking its elite AA credit rating. ✌️🙏❤️‍🩹

$JNJ $MRNA $SLS Shorts got 20 minutes to close there positions or get liquidated while trying. Time just ran out. 🔥 ✌️🙏❤️‍🩹

$JNJ will be leader in oncology in the future, especially should they (hopefully) acquire $SLS

$JNJ $SLS Basic Stats Short Interest Statistics Short Interest 57,926,912 Shares - source: NASDAQ Short Interest Ratio 11.73 Days to Cover Looking like Shorts just ran out of time !

$JNJ NOV20 265C · still actionable Zone: $252.01 to $255.57 Invalidation: close under $245.17 Objectives: $265.35, then $281.07 The math: up 4.6% to the first objective and 10.7% to the second, against 3.4% risk on the invalidation, better than 3 to 1 to the second Dear friend, picture a big steady company that just took a hard knock and then stood back up. Johnson and Johnson beat its October 13 earnings estimate and the stock fell to $245.17 that day, then buyers stepped in and held the price above that low through a choppy week. That is a swing setup to me, a washed out name holding a real level with room to walk back toward $265.35 first. What that means is simple, we risk a close under the earnings day low to see if the bounce can grow legs. P.S. Watch $251.50, the low from the latest session, because holding above it keeps the bounce picture clean.

$JNJ | JOHNSON & JOHNSON Q3 2026 EARNINGS HIGHLIGHTS ◆ EPS: $2.59 vs. $2.52 est. ✅ ◆ Revenue: $25.40B vs. $25.38B est. ✅ ◆ Adjusted Net Earnings: $6.34B (-6.8% YoY) ◆ Net Income: $0.21B (-95.9% YoY) ◆ YTD Free Cash Flow: ~$15.10B (+6.1% YoY) ◆ Innovative Medicine Sales: $16.76B (+7.7% YoY) Segment Performance: ◆ Innovative Medicine: $16.76B (+7.7% YoY) ◆ MedTech: $8.64B (+2.5% YoY) Key Metrics: ◆ GAAP EPS of $0.09 (vs. $2.12 prior year) reflects one-time talc litigation charge, Firefly Bio acquisition, and Sail Biomedicines collaboration. ◆ JNJ announced a proposed resolution of ovarian talc litigation, a significant contingent liability for the company. ◆ FDA approved IMAAVY for wAIHA and authorized OTTAVA robotic surgical system; RYBREVANT FASPRO received Priority Review. Forward Guidance: ◆ FY2026 Estimated Reported Sales: $101.0B-$101.4B (midpoint $101.2B), +7.2%-7.6% YoY; raised from prior midpoint of $101.1B. ◆ FY2026 Adjusted EPS (Diluted): $11.05-$11.15 (midpoint $11.10), +2.4%-3.3% YoY; raised $0.06 from prior midpoint. ◆ FY2026 Adjusted Operational EPS (Diluted): $10.95-$11.05 (midpoint $11.00), +1.5%-2.4% YoY; raised from prior midpoint of $10.94. ◆ FY2026 Adjusted Operational Sales growth: 6.4%-6.8% (midpoint 6.6%); raised from prior midpoint of 6.5%.

$JNJ Trending from 5 posts today? One Ai pic I stole from a Sellas homie, reshared 2 times, eyeballs 👀, and a comment about earnings Tuesday. What kind of scam site is this? 🤣 Oh 40 Billy buyout or bust.

$JNJ Load up on the drop! Happens on earnings with JNJ but shares recover. Very positive comments from Jim Creamer on MAD Money.

$JNJ "Trade Idea 2: Buy the October 265/267.50 Call Spread ($1.30) and sell the October 252.50 Put for 25 cents." looks to expire, a bust. can buy to close puts after IV falls to release margin

$JNJ This will be a lot higher next week with rotation out of technology stocks and into blue chip, defensive, safe quality with great dividend payout to boot🚀🚀🚀🚀

$JNJ I think what he's trying to say is STFU. This experience will be much more enjoyable after muting you

https://www.cnbc.com/2026/10/09/jim-cramer-week-ahead-bank-earnings-ai-chips.html $JNJ Club holding Johnson & Johnson also reports Tuesday. Cramer said the stock often sells off during its earnings call despite strong underlying results, creating a potential buying opportunity. “With 18 potential blockbuster drugs in the pipeline and among the best cardio and oncology franchises, J&J needs to be bought when it gets crushed,” he said.

$JNJ: 70,712 talc actions have passed through MDL 2738 in total, with 68,029 still pending on June 1. No nationwide settlement followed them. J&J denies the allegations, individual suits only. Open Class Actions.

$JNJ should explode to higher highs before coming back down a bit. buy some calls, then cash out

$JNJ Strange tape for J&J today. It beat on the headline numbers and raised guidance, yet JNJ is near 245.52, down about 6.90 percent. The problem is MedTech. Device sales rose 2.5 percent to 8.6 billion, short of the 8.71 billion expected, the second straight quarterly miss. The CFO pointed to the Middle East conflict, European austerity, and China pricing. Everything else looked solid. Revenue of 25.4 billion and adjusted EPS of 2.59 both topped estimates, the full year EPS outlook rose to 11.10 at the midpoint, and Tremfya jumped 68 percent to 2.4 billion. The orthopedics spinoff is still on track for mid 2027. Boston Scientific and Intuitive Surgical were lower too, though one analyst cautioned against reading J&J's issues across the whole sector. Follow me for more on the healthcare names.

$JNJ Q3 2026: Reported earnings COLLAPSED 95.9% to $210M from $5.15B a year ago. GAAP EPS plunged 95.8% to $0.09 from $2.12. J&J cited a one-time charge for its proposed talc litigation resolution, the Firefly Bio acquisition and its Sail Biomedicines collaboration. Revenue rose 5.9% to $25.4B, beating the $25.28B analyst consensus reported by Reuters. Adjusted EPS of $2.59 beat the $2.54 consensus but fell 7.5% year over year. J&J raised 2026 guidance to $101.2B in reported sales and $11.10 adjusted EPS at the midpoint. Innovative Medicine sales grew 7.7%; MedTech rose 2.5%. TREMFYA sales jumped 68% to $2.4B, while STELARA fell 54% to $716M amid generic competition. Investor takeaway: Better guidance and pharma growth are positives, but the steep reported earnings decline and ongoing litigation risk warrant scrutiny. (Source: J&J)